

SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Informs Investors of a Lawsuit Against Fulgent Genetics, Inc.

Class action lawsuit charges Fulgent Genetics and certain of its top executive officers with violations of the Securities Exchange Act of 1934.

NASHVILLE, TENNESSEE, UNITED STATES, September 21, 2022 /EINPresswire.com/ -- The Law Offices of [Timothy L. Miles](#), who has been leading the fight to protect shareholder rights for over 20 years, informs investors that a that a purchaser of Fulgent Genetics, Inc. (NASDAQ: FLGT) who suffered losses in Palantir stock, filed a class action complaint against the Company for violations of the securities laws. The Fulgent Genetics

class action lawsuit seeks to represent purchasers or acquirers of Fulgent securities between March 22, 2019 and August 4, 2022, inclusive (the "Class Period"). The Fulgent Genetics class action lawsuit – captioned Pugley v. Fulgent Genetics, Inc., No. 22-cv-06764 (C.D. Cal.) – charges Fulgent Genetics and certain of its top executives with violations of the Securities Exchange Act of 1934.



Fulgent Genetics Shareholders Are Urged to Contact the Firm (24/7) for Additional Information or Questions at no charge"

Timothy L. Miles

If you suffered losses in Fulgent Genetics stock or would like additional information, please [visit us here](#).

Allegations in the Fulgent Genetics Class Action Lawsuit

Fulgent Genetics provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients. Fulgent Genetics must comply with the federal Anti-Kickback Statute, which prohibits the knowing and willful payment of "remuneration" to induce or reward patient referrals or the generation of business involving any item or service



LAW OFFICES OF
Timothy L. Miles
Champion of the Underdog

109 Summit Ridge Ct.
Nashville, TN 37215

FIRM ANNOUNCEMENT

SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Informs Investors of a Lawsuit Against Fulgent Genetics, Inc.

855-Tim-M-Law


SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Informs Investors of a Lawsuit Against Fulgent Genetics, Inc.

payable by the federal health care programs, as well as the federal Stark Law, which prohibits a physician from making referrals for certain designated health services, including laboratory services, that are covered by the Medicare program, to an entity with which the physician or an immediate family member has a direct or indirect financial relationship.

The Fulgent Genetics class action lawsuit alleges that defendants failed to disclose that: (i) Fulgent Genetics had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (ii) accordingly, Fulgent Genetics was likely to become subject to enhanced legal and regulatory scrutiny; (iii) Fulgent Genetics' revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; and (iv) the foregoing, once revealed, was likely to subject Fulgent Genetics to significant financial and/or reputational harm.

On August 4, 2022, Fulgent Genetics released its second quarter 2022 financial results, disclosing, among other items, that the U.S. Securities and Exchange Commission ("SEC") was conducting an investigation into certain of Fulgent Genetics' reports filed with the SEC from 2018 through the first quarter of 2020.

The disclosure followed Fulgent Genetics' receipt of a civil investigative demand issued by the U.S. Department of Justice related to its "investigation of allegations of medically unnecessary laboratory testing, improper billing for laboratory testing, and remuneration received or provided in violation of the Anti-Kickback



Nationally Recognized Shareholder Rights Attorney Timothy L. Miles



Nationally Recognized Personal Injury Attorney Timothy L. Miles Receives 2022 AV Preeminent Recognition

Statute and the Stark Law." On this news, Fulgent Genetics' stock price fell by more than 17%, damaging investors who suffered losses in Fulgent Genetics stock.

Fulgent Genetics Shareholders Urged to Contact the Firm

If you purchased Fulgent Genetics securities, have information, or have any questions concerning this announcement or your rights or interests with respect to these matters, please [click here](#) for more information or contact Timothy L. Miles, Esquire, Toll-Free at 855-846-6529, or by email to tmiles@timmileslaw.com. If you inquire by email please include your mailing address, telephone number, and the number shares owned.

About Timothy L. Miles

Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles was recently selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer and a 2022 Top Rated Litigator. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association, a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019).

Awards: Top Rated® Litigator by Martindale-Hubbell® and ALM (2019); 2019 Elite Lawyer of The South by Martindale-Hubbell® and ALM (2019); Member of the Top 100 Civil Plaintiff Trial



Nationally Recognized Shareholder Rights Attorney
Timothy L. Miles



Timothy L. Miles, a nationally recognized shareholder rights attorney

Lawyers: The National Trial Lawyers Association (2017-2019); AV® Preeminent™ Rating by Martindale-Hubbell® (2014-2020); PRR AV Preeminent Rating on Lawyers.com (2017 & 2019); The Top-Rated Lawyer in Litigation™ for Ethical Standards and Legal Ability (Martindale-Hubbell® 2015); Lifetime Achievement Award by Premier Lawyers of America (2019); Superb Rated Attorney (Avvo); Avvo Top Rated Lawyer for (Avvo 2017-2020). Mr. Miles has authored numerous publications advocating for shareholdings including most recently: Free Portfolio Monitoring Services Offered by Plaintiff Securities Firms Provides Significant Benefits To Investors (Timothy L. Miles, Dec. 3, 2019).

Contact:

Timothy L. Miles, Esq.

Law Offices of Timothy L. Miles

109 Summit Ridge Ct.

Nashville, TN 37215

Telephone: (855-846-6529)

Email: tmiles@timmileslaw.com Website: www.classactionlawyertn.com

Timothy Miles

Law Offices Of Timothy L. Miles

+1 855-846-6529

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

Timothy L. Miles Miles

Law Offices Of Timothy L. Miles

+1 615-587-7384

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

Timothy Miles

Law Offices Of Timothy L. Miles

+1 855-846-6529

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

Timothy L. Miles

Law Offices Of Timothy L. Miles

+1 855-846-6529

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

Timothy L. Miles

Law Offices Of Timothy L. Miles

+1 855-846-6529

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

Timothy L. Miles

Law Offices Of Timothy L. Miles

+1 855-846-6529

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/592078810>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.